Results 11 to 20 of about 4,484 (145)

Metastasis of Hepatocellular Carcinoma to the Urinary Bladder: A Case Report and Literature Review. [PDF]

IJU Case Rep
ABSTRACT Introduction Although secondary bladder tumors from distant metastases are rare, those originating from hepatocellular carcinoma are particularly uncommon, with only a few cases reported to date. Case Presentation An 81 year old male with hepatocellular carcinoma developed a rapidly growing 23 mm‐sized bladder tumor during systemic therapy ...
Fukagawa E, Oka S, Sakaguchi K, Yamamoto S, Ikemura M, Akuta N, Urakami S.   +6 more
europepmc   +2 more sources

Trends in Use of Direct-Acting Antivirals for Treatment of Hepatitis C Virus Infection in Australia 2016-2024. [PDF]

J Viral Hepat
ABSTRACT Direct‐acting antivirals (DAAs) have transformed hepatitis C virus (HCV) treatment in Australia since their inclusion on the Pharmaceutical Benefits Scheme (PBS) in 2016. Treatment has shifted from genotype‐specific to pan‐genotypic regimens, with glecaprevir/pibrentasvir and sofosbuvir/velpatasvir now recommended in clinical guidelines.
Luong CL, Ellett LK, Pratt N, Staff K, Janetzki J.   +4 more
europepmc   +2 more sources

A Comprehensive Molecular and Clinical Investigation of Approved Anti-HCV Drugs Repurposing against SARS-CoV-2 Infection: A Glaring Gap between Benchside and Bedside Medicine

Vaccines, 2023
The limited availability of effective treatment against SARS-CoV-2 infection is a major challenge in managing COVID-19. This scenario has augmented the need for repurposing anti-virals for COVID-19 mitigation.
Sneha Bansode, Pawan Kumar Singh, Meenakshi Tellis, Anita Chugh, Narendra Deshmukh, Mahesh Gupta, Savita Verma, Ashok Giri, Mahesh Kulkarni, Rakesh Joshi, Dhruva Chaudhary   +10 more
doaj   +1 more source

Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent.

PLoS ONE, 2015
Ledipasvir, a direct acting antiviral agent (DAA) targeting the Hepatitis C Virus NS5A protein, exhibits picomolar activity in replicon cells. While its mechanism of action is unclear, mutations that confer resistance to ledipasvir in HCV replicon cells ...
Hyock Joo Kwon, Weimei Xing, Katie Chan, Anita Niedziela-Majka, Katherine M Brendza, Thorsten Kirschberg, Darryl Kato, John O Link, Guofeng Cheng, Xiaohong Liu, Roman Sakowicz   +10 more
doaj   +1 more source

Treatment of Chronic HCV Infection with Direct Acting Antivirals

Central Asian Journal of Medical Sciences, 2021
Objectives: This study was conducted to discover the treatment outcome and side effects of chronic hepatitis C virus patients treated with Direct-Acting Antivirals (DAAs).
Bekhbold Dashtseren, Zulkhuu Genden, Odgerel Oidovsambuu, Anir Enkhbat, Ganbolor Jargalsaikhan, Sumiya Byambabaatar, Myammarsuren Shagdarsuren, Altankhuu Murdorj, Oyungerel Ravjir, Naranbaatar Dashdorj, Naranjargal Dashdorj, Dagvadorj Yagaanbuyant, Batbaatar Gunchin   +12 more
doaj   +1 more source

Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients

The Saudi Journal of Gastroenterology, 2019
Background/Aims: Ledipasvir/sofosbuvir (LDV/SOF) combination is administered for 12 to 24 weeks to treat hepatitis C virus (HCV); guidelines recommend 8 weeks treatment duration for HCV genotype (GT) 1 infection based on the patient's baseline ...
Mohammed A Babatin, Abdullah S AlGhamdi, Abdullah M Assiri, Haziz AlBiladi, Hammad S AlOthmani, Mohammed H Mogharbel, Wedad Mahallawi, Tarik Asselah, Faisal M Sanai   +8 more
doaj   +1 more source

Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication

Cells, 2021
The rapid spread of the virus, the surge in the number of deaths, and the unavailability of specific SARS-CoV-2 drugs thus far necessitate the identification of drugs with anti-COVID-19 activity.
Rameez Hassan Pirzada, Muhammad Haseeb, Maria Batool, MoonSuk Kim, Sangdun Choi   +4 more
doaj   +1 more source

Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8 week regimen in a real-world setting

Archives of Medical Science, 2019
Introduction Non-cirrhotic treatment-naive hepatitis C patients infected with genotype 1 can be treated with ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks, but in practice this regimen is frequently extended up to 12 weeks at least in part due to ...
Dorota Zarębska-Michaluk, Anna Piekarska, Jerzy Jaroszewicz, Jakub Klapaczyński, Marek Sitko, Magdalena Tudrujek-Zdunek, Krzysztof Tomasiewicz, Teresa Belica-Wdowik, Paweł Pabjan, Beata Lorenc, Agnieszka Czauż-Andrzejuk, Olga Tronina, Rafał Krygier, Witold Dobracki, Iwona Buczyńska, Krzysztof A. Simon, Dorota Dybowska, Waldemar Halota, Małgorzata Pawłowska, Jolanta Citko, Łukasz Laurans, Włodzimierz Mazur, Ewa Janczewska, Łukasz Socha, Zbigniew Deroń, Hanna Berak, Robert Flisiak   +26 more
doaj   +1 more source

Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?

The Turkish Journal of Gastroenterology, 2021
Background: In this study, we aimed to investigate the efficacy and safety of sofosbuvir-based therapies in the treatment of chronic hepatitis C in real-world clinical practice. Methods: Data from patients with chronic hepatitis C treated with SOF/LDV ±
Neşe Demirtürk, Bilgehan Aygen, İlhami Çelik, Reşit Mıstık, Sıla Akhan, Şener Barut, Onur Ural, Ayşe Batırel, Funda Şimşek, Gülden Ersöz, Dilara İnan, Sami Kınıklı, Nesrin Türker, Hüseyin Bilgin, Yunus Gürbüz, Necla Tülek, Hüseyin Tarakçı, Orhan Yıldız, Emine Türkoğlu, Deniz Kamalak Güzel, Sümeyra Şimşek, Nazan Tuna, Nazlım Aktuğ Demir, Atahan Çağatay, Rıza Aytaç Çetinkaya, Faruk Karakeçili, İsmail Necati Hakyemez, Günay Tuncer Ertem, Bahar Örmen, Pınar Korkmaz, Uluhan Yıldız, Ziya Kuruüzüm, Alper Şener, Selcan Arslan Özel, Sinan Öztürk, Kaya Suer, Mustafa Kemal Çelen, Petek Konya, Ali Asan, Neşe Saltoğlu, Nurhan Doğan   +40 more
doaj   +1 more source

Development and validation of stability indicating RP-HPLC method for the simultaneous estimation of Sofosbuvir and Ledipasvir in bulk and their combined dosage form

Future Journal of Pharmaceutical Sciences, 2018
Objective: A simple, specific, accurate and economic reverse phase liquid chromatographic method was developed for the simultaneous estimation of Sofosbuvir and Ledipasvir in bulk and tablet dosage form.
S.K. Mastanamma, S.K. Chandini, S.K. Reehana, P. Saidulu   +3 more
doaj   +1 more source